With advances in genetic research technologies, various types of causative genetic aberrations associated with disorders can be studied prenatally with chromosomal microarray analysis (CMA). Because of the increased density and exceptional resolution compared to traditional karyotypes, CMA is rapidly becoming the established method for prenatal genetic research. In fact, American College of Obstetricians and Gynecologists (ACOG) proposes that CMA be used as the primary prenatal genetic analysis method of choice. This is based on the major advantage of CMA over standard karyotyping in terms of discovery yield. 

Thermo Fisher Scientific provides high-resolution microarray research solutions that cytogeneticists trust to improve accuracy and efficiency. With reproducible results, automated data interpretation and hands-on support, Thermo Fisher Scientific is your trusted partner from start to finish.